Taiho’s Lytgobi Faces Heavy Competition, But Sets Efficacy Bar For Now
The FGFR inhibitor beats prior entrants on efficacy in cholangiocarcinoma, although Relay presented data at ESMO for its investigational RLY-4008 showing especially high efficacy and tolerability.
